Abstract

Background

Vaccination with inactivated (killed) whole-virus particles has been used to prevent a wide range of viral diseases. However, for an HIV vaccine this approach has been largely negated due to inherent safety concerns, despite the ability of killed whole-virus vaccines to generate a strong, predominantly antibody-mediated immune response in vivo. HIV-1 Clade B NL4-3 was genetically modified by deleting the nef and vpu genes and substituting the coding sequence for the Env signal peptide with that of honeybee melittin signal peptide to produce a less virulent and more replication efficient virus. This genetically modified virus (gmHIV-1NL4-3) was inactivated and formulated as a killed whole-HIV vaccine, and then used for a Phase I human clinical trial (

Details

Title
First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses
Author
Choi, Eunsil; Michalski, Chad J; Seung Ho Choo; Kim, Gyoung Nyoun; Banasikowska, Elizabeth; Lee, Sangkyun; Wu, Kunyu; Hwa-Yong An; Mills, Anthony; Schneider, Stefan; U Fritz Bredeek; Coulston, Daniel R; Ding, Shilei; Finzi, Andres; Tian, Meijuan; Klein, Katja
Publication year
2016
Publication date
2016
Publisher
BioMed Central
e-ISSN
17424690
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
1846257003
Copyright
Copyright BioMed Central 2016